Establish an appropriate administration schedule for oxaliplatin in mfolfox in patients on hemodialysis: an evidence-based approach

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: YEH, Hui-Yin (En Chu Kong Hospital, New Taipei City, China Taiwan)
  • Co-author(s): Hui-Yin Yeh: Department of Pharmacy, En Chu Kong Hospital, New Taipei City, Taiwan, Province of China
    Chia-Hua Lee: Department of Pharmacy, En Chu Kong Hospital, New Taipei City, Taiwan, Province of China
  • Abstract:

    Methods

    A 58-year-old male on hemodialysis was diagnosed with rectal cancer (pT3N1bM0,stage IIIB), and the mFOLFOX regimen was prescribed. We performed an evidence-based process to determine the dosage of oxaliplatin and make it a policy of our hospital.

    Results

    Free platinum levels, account for the antitumor activity and toxicity of oxaliplatin,..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login